Belantamab mafodotin is a Monoclonal Antibody Conjugated owned by GSK, and is involved in 47 clinical trials, of which 4 were completed, 36 are ongoing, and 7 are planned.

Belantamab mafodotin (GSK-2857916) is directed against the B-cell maturation antigen (BCMA), conjugated to the auristatin analogue and microtubule inhibitor monomethyl auristatin phenylalanine (MMAF). The drug candidate is selectively binds to the BCMA on tumor cell surfaces. Upon internalization, the MMAF moiety binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces tumor cell apoptosis. In addition, GSK2857916 induces antibody-dependent cellular cytotoxicity (ADCC). BCMA, a receptor for a proliferation-inducing ligand and B-cell activating factor, is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma survival.

The revenue for Belantamab mafodotin is expected to reach a total of $11.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Belantamab mafodotin NPV Report.

Belantamab mafodotin is originated and owned by GSK.

Belantamab mafodotin Overview

Belantamab mafodotin (Blenrep) is a B-cell maturation antigen (BCMA)-directed antibody is produced in a mammalian cell line (Chinese Hamster Ovary) using recombinant DNA technology. It is formulated as lyophilized powder for solution for intravenous route of administered. Blenrep is indicated for the treatment multiple myeloma of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

The drug candidate is under development for the treatment of relapsed or refractory plasmablastic lymphoma or ALK+ large B-cell lymphoma, relapsed or refractory AL amyloidosis, relapsed or refractory AL amyloidosis, relapsed or refractory multiple myeloma, diffuse large B-Cell lymphoma and follicular lymphoma

GSK Overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020. The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.

Quick View – Belantamab mafodotin

Report Segments
  • Innovator (NME)
Drug Name
  • Belantamab mafodotin
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Metabolic Disorders
  • Oncology
Key Companies
  • Sponsor Company: GSK
  • Originator: GSK
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.